Seqirus announced the U.S. Food and Drug Administration (FDA) has approved Afluria Quadrivalent (Influenza Vaccine) for use in people six months of age and older. The approval also applies to the trivalent formulation of Afluria (Influenza Vaccine).
Afluria Quadrivalent was first approved in the U.S. in August 2016, for adults aged 18 years and above and helps protect against two influenza A strain viruses and two B strain viruses.
"Younger children, who are more at risk for getting the flu because of their weaker immune systems, are a priority population for Seqirus," said Gordon Naylor, President of Seqirus. "As a company on the front line of influenza protection, the approval of Afluria Quadrivalent for children six months and older is reflective of our dedication to providing broad and effective options across a variety of ages."
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
Afluria Quadrivalent is available in the U.S. for the 2018-2019 influenza season, presented in pre-filled syringes as well as multi-dose vials.
The U.S. Centers for Disease Control and Prevention (CDC) recommends an annual influenza vaccine for everyone six months of age and older as the first and most important step in protecting against influenza and its potentially serious complications.
"As we enter a new flu season, we are reminded of the enormous impact that influenza can have on public health," said Gregg Sylvester MD, Vice President of Medical Affairs at Seqirus. "Having another option to fight this disease can translate to saved lives and fewer flu-related hospitalizations this season and going forward."
The complete Seqirus portfolio of seasonal influenza vaccines provides a range of options for children aged six months of age to people aged 65 years and older, including egg-based and cell-based technologies and adjuvant.